Navigation Links
Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
Date:8/20/2010

viding innovative products which improve quality of care for patients. The Company completed the initial public offering of its common stock in August 2009. For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.

Important Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that reflect Cumberland's current views with respect to future events, based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of operations are subject to influences outside of the Company's control. Risk factors that could materially affect results of operations include, among others, those factors discussed in Cumberland's Registration Statement declared effective by the SEC on August 10, 2009. There can be no assurance that results or developments anticipated by Cumberland will be realized or, even if realized, that they will have the expected effects. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Cumberland undertakes no obligation to release publicly any revisions to these statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Investor Contact:Angela NovakCumberland Pharmaceuticals615-255-0068investors@cumberlandpharma.comMedia Contact:Rebecca KirkhamLovell Communications615-297-7766rebecca@lovell.com
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
5. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
6. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- ExeGi Pharma, a company focused on developing and ... it has been granted a product license by the ... to sell Visbiome™ in Canada . ... Claudio De Simone , MD, PhD and has been ... recently signed an exclusive agreement with ExeGi Pharma to ...
(Date:7/1/2015)... 2015 According to a new ... Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), ... Global Forecast to 2020", published by MarketsandMarkets, the Transfection ... $957.9 Million by 2020 with a CAGR of 7.2% ... market T ables and 33 F ...
(Date:7/1/2015)... Mass. , July 1, 2015 Boston Scientific ... discussing financial results and business highlights for the second quarter ... 8 a.m. ET. The call will be hosted ... and Dan Brennan , executive vice president and chief ... call will be available via the Boston Scientific website. Webcast ...
Breaking Medicine Technology:ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4Boston Scientific To Webcast Second Quarter 2015 Earnings Call On July 23 2
... WIRE)--May 21, 2007 - Results from a new,study, ... (DDW),conference, showed that more than 99 percent of ... were treated,successfully with PEGASYS(R) (peginterferon alfa-2a) had no,detectable ... the use of,the word "cured" to describe these ...
... Shows Promising Treatment for People Suffering,from Barrett's ... WILMINGTON, MASSACHUSETTS--(CCNMatthews - May 17, 2007) - ... U.S. Food,and Drug Administration (FDA) has granted ... Photodynamic Therapy (PDT),for the treatment of esophageal ...
Cached Medicine Technology:Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 2Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 3Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 4Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 5Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 6DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan,PDT to Treat Esophage al Dysplasia 2DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan,PDT to Treat Esophage al Dysplasia 3DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan,PDT to Treat Esophage al Dysplasia 4
(Date:7/1/2015)... , ... July 01, 2015 , ... Convoy of ... community celebration in the Twin Cities on Saturday, August 1, at Spring Lake Park ... community will provide more than $1 million worth of goods and services including free ...
(Date:7/1/2015)... Louisville, KY (PRWEB) , ... July 01, 2015 ... ... Health Care Transformation Task Force, contributing to newly released white paper: “Pro-actively Identifying ... The paper was published July 1st and is available at: http://www.hcttf.org/resouces-tools . ...
(Date:7/1/2015)... Columbus, OH (PRWEB) , ... July 01, 2015 , ... ... pleased to announce Dr. Leslie King has been named Dean of the ... role as Dean, Dr. King will promote and support the vision and mission of ...
(Date:7/1/2015)... Luis Obispo, CA (PRWEB) , ... July 01, ... ... non-surgical bunion treatment, announces their big summer sale. Customers purchasing two or ... with promo code "Summer15". , Bunion Bootie temporarily corrects misaligned toes ...
(Date:7/1/2015)... ... ... B. E. Smith, the only full-service leadership solutions firm dedicated exclusively to ... for Capital Health in Pennington, N.J. One of the top ... more than 1,000 healthcare executives into organizations. , Capital Health is a two-hospital ...
Breaking Medicine News(10 mins):Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:Franklin University Appoints Dean of College of Health & Public Administration 2Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... A team of French surgeons took off on a specially ... attempt the first-ever operation // carried out in weightless ... ,The Airbus A300 is equipped with a special surgical module, ... future surgery carried out in the gravity-free conditions of outer ...
... of patented drugs will play host to a new entrant ... recent communique // by the Director of patent policy in ... arm for the multitude of generic drug manufacturers, who can ... to developing nations. ,Biolyse Pharma Corp., ...
... in the U.S. uncovered the secrets of the deadly Spanish flu ... across the world.// ,The pandemic took lives of ... severity of the virus was not understood then. ,Dr John Kash, ... a research by infecting mice with a reconstructed form of the ...
... Thiruvananthapuram: The Health Department has announced that it ... both prevention as well as // control measures, ... districts in Kerala, Thiruvananthapuram, Alappuzha, Ernakulum and Kozhikode ... of a slackened response by the Health watch ...
... a division that deals with the reconstruction of the ... the occurrence of birth defects like cleft palate. Since ... required. This will not only ensure a smooth operation, ... their face will look like in future., ,In ...
... cornea cells that may also explain how it evades the ... University of Illinois at Chicago College of Medicine. ... Journal of Cell Biology. ,Both strains of the ... on the mouth, and HSV-2, genital herpes -- can infect ...
Cached Medicine News:Health News:Spanish flu virus – secrets uncovere 2Health News:Mathematics And Beauty? You Bet! 2Health News:Herpes Infects Cornea, Evades Immune Cells 2
PDA application contains 15,000+ ICD-9-CM Diagnosis codes....
Contains the most common procedures from all orthopedic sub-specialties organized by body area....
Athouritative, on the spot answers for acute care and consultations....
Product includes all 15 Lexi-Comps databases. Includes Lexi-drugs, the official reference of the American Pharmacists Association and the National Professional Society of Pharmacists....
Medicine Products: